XOMA (NASDAQ:XOMA) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $74.00 target price on the biotechnology company’s stock.

Separately, SVB Leerink began coverage on XOMA in a report on Monday, April 29th. They issued an outperform rating and a $40.00 price target on the stock.

XOMA Trading Down 2.6 %

Shares of XOMA stock opened at $24.78 on Wednesday. The company has a market capitalization of $288.44 million, a P/E ratio of -6.13 and a beta of 0.57. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34. The business’s 50 day moving average is $25.13 and its two-hundred day moving average is $20.77. XOMA has a twelve month low of $13.48 and a twelve month high of $27.00.

XOMA (NASDAQ:XOMA) last released its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. The business had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. Equities analysts forecast that XOMA will post -2.11 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in XOMA stock. BNP Paribas Financial Markets boosted its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 55.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,543 shares of the biotechnology company’s stock after purchasing an additional 1,266 shares during the period. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 as of its most recent SEC filing. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.